Absci entered its new drug into Phase I trials in half the time and for many millions of dollars less than it would have cost without AI.

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...

A research team from the University of Oklahoma has pioneered a method that could accelerate drug discovery and reduce pharmaceutical development costs. Their work, published in the Journal of the ...

The firm's methods - using real human tissue samples in the lab - give drug developers a more accurate picture of how their ...

CEO Dan O'Connell reported that Acumen completed enrollment of its 542-participant Phase 2 ALTITUDE-AD study evaluating Sabirnetug for early Alzheimer’s disease, stating, "We completed enrollment of ...

In vitro testing with CDI-988 demonstrated superior broad-spectrum antiviral activity against major norovirus variants BOTHELL, W ...

AGC Biologics, your friendly CDMO expert, today announced a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea. Novelty Nobility will leverage AGC ...

Factors Affecting the Growth of the Artificial Intelligence For Drug Development and Discovery Industry: ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA ...